CAMCEVI

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, Lithuania, Romania.

Active ingredients

The drug CAMCEVI contains one active pharmaceutical ingredient (API):

1	Leuprorelin UNII 8E3C3C493W - LEUPROLIDE MESYLATE
	Leuprorelin is inactive when given orally due to poor membrane permeability and an almost complete inactivation by intestinal proteolytic enzymes. Leuprorelin has potent LHRH agonist properties when given during short-term and intermittent therapy, however, when administered in a continuous, nonpulsatile manner, LHRH analogs induce inhibition of gonadotropin secretion and suppression of testicular steroidogenesis.
	Read more about Leuprorelin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAMCEVI Prolonged-release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AE02	Leuprorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1885035
LT	Valstybinė vaistų kontrolės tarnyba	1094953
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68882001
US	FDA, National Drug Code	69448-014